Mononegavirales infectious disease

This early-stage trial is testing two mRNA vaccines in children aged 5 months to under 24 months. One vaccine targets RSV alone, and the other targets both RSV and hMPV. The main goals are to check safety and see how well the vaccines trigger an immune response. About 186 childre…

This study examines how well the ABRYSVO vaccine works when given during pregnancy to prevent RSV in infants. Researchers will compare health outcomes of babies born to vaccinated mothers versus unvaccinated mothers using electronic medical records. The goal is to see if the vacc…

This study looks at whether a booster dose of the Ebola vaccine (ERVEBO) can strengthen the immune system of people who have already survived Ebola. Researchers will compare their response to that of healthy people who have never had the virus. The goal is to see if the booster p…

This study was designed to check how long the Ebola vaccine (ERVEBO) protects people who might be exposed at work, like lab workers or healthcare staff. It also planned to see if a booster shot could extend that protection. However, the trial was withdrawn before enrolling any pa…

This massive study is testing whether the Abrysvo RSV vaccine can prevent hospitalizations due to RSV in adults aged 18 and older. Half of the 690,000 participants will receive the vaccine, while the other half will not. Researchers will track how many in each group end up hospit…

This study looks at the best timing for a booster shot of the RSV vaccine in adults aged 60 and older. It will follow over 10,000 participants for up to 5 years to see how long protection lasts and whether a second dose is needed. The goal is to help prevent serious RSV infection…

This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. About 612 healthy adults aged 60-85 will receive either a vaccine or a placebo. The main goal is to check safety and how well the vaccines tr…

This early-stage study tests a new vaccine called VXB-241 in healthy adults aged 60-83, with a smaller group of younger adults (18-40) first. The vaccine is designed to protect against two viruses that can cause serious lung infections: RSV and HMPV. Researchers will check how sa…

This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers…

This study checks how well the ABRYSVO® vaccine protects infants from severe RSV when given to pregnant women. Researchers will look at hospital records from Argentina and Uruguay over several RSV seasons. The goal is to see if the vaccine reduces hospitalizations and severe illn…

This study reviews medical records to see how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV lung infections in adults 60 and older. Researchers will analyze existing health data from routine doctor visits over several years. No new treatments or active participat…

This phase 3 trial is testing a non-live, adjuvanted RSV vaccine (Arexvy) in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants…

This early-stage study tests an experimental mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy volunteers, split into two age groups (18-45 and 60+), will receive either the vaccine or a pla…

This early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune respo…

This study tests an experimental nasal vaccine made from a harmless virus (Sendai virus) that is similar to the one causing croup. The goal is to see if it is safe and helps children ages 1 to 5 build protection against croup. About 54 children will receive the vaccine as nose dr…

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses of the vaccine at dif…

This study tests a new vaccine called LYB005 against RSV, a virus that can cause serious lung infections in older adults. About 700 volunteers aged 60 and older will receive either the vaccine or a placebo. Researchers will check how well the vaccine boosts the immune system and …

This study tests an experimental vaccine against Sudan ebolavirus in 200 healthy adults aged 18 to 70. The vaccine uses a harmless chimpanzee virus to deliver protection. Researchers will check for side effects and measure immune responses 29 days after vaccination. The goal is t…

This study looks at how well the ABRYSVO vaccine, given to pregnant women, protects their babies from RSV, a leading cause of severe lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in western Pennsylvania over several RSV seasons…

This study is checking the safety of the Abrysvo RSV vaccine in adults aged 60 and older in everyday medical practice in Japan. About 1100 people who get the vaccine will be watched for side effects for 28 days. The goal is to confirm the vaccine is safe for older adults.

This Phase 3 study tests whether a single dose of Pfizer's RSV vaccine (RSVpreF) can prevent lower respiratory tract illness caused by RSV in adults aged 60 and older. Over 38,800 participants across multiple countries received either the vaccine or a placebo. The study also look…

This study tests an experimental vaccine against Marburg virus, a rare but severe disease. About 200 healthy adults will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and prompts the body …

This phase 2 trial is testing a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive either a low or high dose of the vaccine or a placebo. The study measures how well the vaccine boosts antibodies…

This early-stage trial tests a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV). Around 96 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.

This study tests a new mRNA vaccine designed to protect adults aged 60 and older from two viruses that can cause serious lung infections: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). About 1,530 participants will receive either the vaccine or a placebo to c…

This early-stage trial is testing two new mumps vaccines given as a nasal spray, called CVM150 and CVM26, in up to 60 healthy adults aged 18-29. The main goal is to check if they are safe and to see how well they trigger an immune response. Unlike traditional shots, these vaccine…

This early-stage trial is testing several doses of an experimental mRNA vaccine against RSV in 213 healthy adults aged 18-45. The goal is to check the vaccine's safety and how well it triggers an immune response. Participants receive two shots, and researchers monitor for side ef…

This study tests a new mRNA vaccine called IN006 against respiratory syncytial virus (RSV) in 500 healthy adults aged 60 and older. The vaccine is given as two different doses, with a booster after 12 or 24 months. Researchers will monitor safety and measure immune responses like…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study tests two new devices (imPulse Una and TOR) that use sound waves to detect COVID-19, flu, and RSV without needles or swabs. About 300 adults with or without symptoms will have a quick, painless scan. The goal is to see if these e-stethoscopes can accurately identify th…

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and young children. About 110 infants and toddlers up to 24 months old will receive the medicine as part of their regular care. Researchers will track side effects and how many children ge…

This study aimed to test whether the drug obeldesivir could safely prevent filovirus diseases like Ebola in people who had been exposed. It was designed for adults with known or suspected high-risk contact within the past 21 days. However, the study was withdrawn before enrolling…

This study compares two methods to prevent RSV, a common virus that can cause serious breathing problems in babies. One method is a vaccine given to pregnant women, which passes protection to the baby before birth. The other is an antibody shot given directly to the newborn. The …

This study checks how well the RSV vaccine (ABRYSVO) works when given to pregnant women to protect their babies from severe RSV illness. Researchers will look at health records of infants hospitalized with breathing problems in Australia. They want to see if vaccinated moms' babi…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study follows 300 pregnant women who had respiratory infections to see if RSV can pass from mother to baby before birth. Researchers will test blood from mothers and umbilical cords for RSV antibodies and viruses. Babies will be tracked for up to 4 years to monitor respirato…

This study follows 500 children under 18 who tested positive for flu, RSV, or COVID-19. Each child takes a daily nose swab for 14 days to measure how the virus levels change over time. Researchers also check if family members get sick. The goal is to understand when kids are most…

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study gives 30 healthy adults a single dose of the approved Ebola vaccine (Ervebo) and tracks their immune responses over time using blood, lymph node, and bone marrow samples. The goal is to understand how long the body 'remembers' the vaccine, which could guide future boos…

This study looks at how the RSV vaccine affects the immune system in adults aged 60 and older. Researchers will take blood samples before and after vaccination to find early signs of protection. The goal is to understand why some people respond better than others. 14 volunteers w…

This study examines medical records of 1,100 children under 18 from hospitals across China who were hospitalized with RSV-positive bronchiolitis or pneumonia between 2017 and 2021. Researchers aim to understand how the disease is diagnosed and treated, and what it costs families …

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…